Tezepelumab reduced the size of nasal polyps and the severity of nasal congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps, in a placebo-controlled study.
"These findings build on the reported efficacy of tezepelumab in patients with severe, uncontrolled asthma and coexisting chronic rhinosinusitis with nasal polyps and suggest that the reduction in multiple downstream inflammatory signaling may modify disease severity in the patients who participated in the present trial," the authors of this study wrote.
Joseph K. Han, MD, with Eastern Virginia Medical School in Norfolk, Virginia, was the corresponding author for the study, which was published online on March 1 in The New England Journal of Medicine. The results were also presented at the American Academy of Allergy, Asthma, & Immunology/World Allergy Organization 2025 Annual Meeting.
The trial included patients with coexisting asthma, but the study was not designed to characterize asthma severity.
This study was supported by AstraZeneca and Amgen, the companies that are developing and manufacturing tezepelumab. Several study authors declared being employees of or consultants for those companies.